The Department of Health and Human Services, through the National Institutes of Health (NIH), is offering a funding opportunity titled "Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U01 Clinical Trial Optional)." The purpose of this funding opportunity is to support the clinical validation of strong candidate biomarkers for neurological and neuromuscular disorders, aiming to establish their clinical sensitivity and specificity according to FDA guidelines. The funding is available for applications that include a well-defined context of use for one or two biomarker types, demonstrating prior preliminary testing and analytical validation. Key dates include an application open date of January 21, 2025, and an expiration date of June 23, 2026. The application requires a Plan for Enhancing Diverse Perspectives (PEDP) and detailed justification of the study design, statistical analysis, and collaborative partnerships. The innovative research is aimed at advancing public health by facilitating appropriate biomarker implementation in clinical settings, reflecting NIH’s goal in enhancing healthcare outcomes for neurological and neuromuscular disorders. Applications that do not adhere to specific guidelines will be eliminated from the review process, ensuring a focus on rigor and scientific merit.